The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma

Journal of Pathology

Volumn 191, Issue 2, 2000, Pages 120-126

  Coupland, Sarah E ^a   Anastassiou, Gerasimos ^b   Stang, Andreas ^b   Schilling, Harald ^b   Anagnostopoulos, Ioannis ^a   Bornfeld, Norbert ^b   Stein, Harald ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UKBF ^*

Author keywords

Cyclin D1; MDM2; P53; Prognosis; Uveal melanoma

Indexed keywords

BIOCHEMICAL MARKER; CYCLIN D1; PROTEIN MDM2; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DIAGNOSTIC VALUE; EYE TUMOR; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOLOGY; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SURVIVAL RATE; UVEA MELANOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CONFIDENCE INTERVALS; CYCLIN D1; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NUCLEAR PROTEINS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REGRESSION ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; UVEAL NEOPLASMS;

EID: 0034129488     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(200006)191:2<120::AID-PATH591>3.0.CO;2-P     Document Type: Article

References (43)

1. Jensen OA. Malignant melanomas of the human uvea: 25-year follow-up of cases in Denmark, 1943-1952. Acta Ophthalmol Copenhagen 1982; 60: 161-182.
2. Seddon JM, Albert DM, Lavin PT, Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 1983; 101: 1894-1899.
3. Kath R, Hayungs J, Bornfeld N, Sauerwein W, Hoffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma [see comments]. Cancer 1993; 72: 2219-2223.
4. Pyrhonen S. The treatment of metastatic uveal melanoma. Eur J Cancer 1998; 34(Suppl 3): S27-S30.
5. Mooy CM, De Jong PT. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 1996; 41: 215-228.
6. Coupland SE, Bechrakis N, Schuler A, et al. Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. Br J Ophthalmol 1998; 82: 961-970.
7. Mouriaux F, Casagrande F, Pillaire MJ, Manenti S, Malecaze F, Darbon JM. Differential expression of G1 cyclins and cyclin-dependent kinase inhibitors in normal and transformed melanocytes. Invest Ophthalmol Vis Sci 1998; 39: 876-884.
8. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 1993; 73: 499-511.
9. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 1993; 73: 487-497.
10. Bartkova J, Lukas J, Strauss M, Bartek J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995; 10: 775-778.
11. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995; 55: 975-978.
12. Sarbia M, Stahl M, Fink U, et al. Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int J Cancer 1999; 84: 86-91.
13. Michalides R, Hageman P, van Tinteren H, et al. A clinico-pathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 1996; 73: 728-734.
14. Gillett C, Smith P, Gregory W, et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996; 69: 92-99.
15. Nielsen NH, Emdin SO, Cajander J, Landberg G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene 1997; 14: 295-304.
16. Muro-Cacho CA, Holt T, Klotch D, Mora L, Livingston S, Futran N. Cyclin D1 expression as a prognostic parameter in papillary carcinoma of the thyroid. Otolaryngol Head Neck Surg 1999; 120: 200-207.
17. Gustafsson B, Stal O, Gustafsson B. Overexpression of MDM2 in acute childhood lymphoblastic leukemia. Pediatr Hematol Oncol 1998; 15: 519-526s.
18. Zietz C, Rossle M, Haas C, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 1998; 153: 1425-1433.
19. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999; 55: 96-107.
20. McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 1983; 96: 502-509.
21. Norton AJ, Jordan S, Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 1994; 173: 371-379.
22. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32: 219-229.
23. Kivela T. Immunohistochemical staining followed by bleaching of melanin: a practical method for ophthalmic pathology [letter; comment]. Br J Biomed Sci 1995; 52: 325-326.
24. Breslow NE, Day NE. The Analysis of Case-Control Studies. Statistical Methods in Cancer Research, vol 1. IARC: Lyon, 1980.
25. SAS Institute, SAS/STAT, User's guide, Version 6 (4th edn), vol 2. SAS Institute: Cary, NC, 1990; 1071-1126.
26. McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol 1982; 13: 123-132.
27. McLean IW, Ainbinder DJ, Gamel JW, McCurdy JB. Choroidal ciliary body melanoma. A multivariate survival analysis of tumor location. Ophthalmology 1995; 102: 1060-1064.
28. Folberg R, Pe'er J, Gruman LM, et al. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case control study. Hum Pathol 1992; 23: 1298-1305.
29. Whelchel JC, Farah SE, McLean IW, Burnier MN. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest Ophthalmol Vis Sci 1993; 34: 2603-2606.
30. de la Cruz PO Jr, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer 1990; 65: 112-115.
31. Blom DJ, Luyten GP, Mooy C, Kerkvliet S, Zwinderman AH, Jager MJ. Human leukocyte antigen class 1 expression. Marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci 1997; 38: 1865-1872.
32. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347: 1222-1225.
33. Karlsson M, Boeryd B, Castensen J, et al. Correlations of Ki-67 and PCNA to DNA ploidy, S-phase fraction and survival in uveal melanoma. Eur J Cancer 1996; 32A: 357-362.
34. Seregard S, Oskarsson M, Spangberg B. PC-10 as a predictor of prognosis after antigen retrieval in posterior uveal melanoma. Invest Ophthalmol Vis Sci 1996; 37: 1451-1458.
35. Wagner U, Süss K, Luginbühl T, et al. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol 1999; 188: 44-50.
36. Shin KY, Kong G, Kim WS, Lee TY, Woo YN, Lee JD. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer 1997; 75: 1788-1792.
37. Janssen K, Kuntze J, Busse H, Schmid KW. p53 oncoprotein overexpression in choroidal melanoma. Mod Pathol 1996; 9: 267-272.
38. Tobal K, Warren W, Cooper CS, McCartney A, Hungerford J, Lightman S. Increased expression and mutation of p53 in choroidal melanoma. Br J Cancer 1992; 66: 900-904.
39. Jay V, Yi Q, Hunter WS, Zielenska M. p53 expression in uveal malignant melanomas. Pathology 1996; 28: 306-308.
40. Chana JS, Wilson GD, Cree IA, et al. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma [in process citation]. Br J Ophthalmol 1999; 83: 110-114.
41. Wynford Thomas D. p53 in tumour pathology: can we trust immunocytochemistry? [editorial] [see comments]. J Pathol 1992; 166: 329-330.
42. Hernberg M, Turunen JP, von Boguslawsly K, Muhonen T, Pyrhonen S. Prognostic value of biomarkers in malignant melanoma. Melanoma Res 1998; 8: 283-291.
43. Wurl P, Meye A, Schmidt H, et al. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene 1998; 16: 1183-1185.